siRNA anti-HMGB1 (Bio3)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamesiRNA anti-HMGB1 (Bio3)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionHigh Mobility Group Protein B1 inhibitors
TargetsHigh Mobility Group Protein B1
Therapy Area/IndicationsAtherosclerosisCoronary Restenosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItaly
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBio3 Research
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBio3 Research
Active IndicationsN/A
Inactive IndicationsAtherosclerosisCoronary Restenosis

Other Information

ATC CodeN/A
Related LinksN/A